Subcutaneous Amivantamab Biologics License Application Submitted to U.S. FDA for Patients With Egfr-Mutated Non-Small Cell Lung Cancer
用於EGFR突變非小細胞肺癌的皮下生物製品Amivantamab的許可申請已提交給美國FDA
Subcutaneous Amivantamab Biologics License Application Submitted to U.S. FDA for Patients With Egfr-Mutated Non-Small Cell Lung Cancer
用於EGFR突變非小細胞肺癌的皮下生物製品Amivantamab的許可申請已提交給美國FDA
譯文內容由第三人軟體翻譯。